Logo image of LTRN

LANTERN PHARMA INC (LTRN) Stock Fundamental Analysis

USA - NASDAQ:LTRN - US51654W1018 - Common Stock

3.36 USD
-0.02 (-0.59%)
Last: 11/17/2025, 4:10:08 PM
Fundamental Rating

2

Taking everything into account, LTRN scores 2 out of 10 in our fundamental rating. LTRN was compared to 533 industry peers in the Biotechnology industry. LTRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LTRN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LTRN had negative earnings in the past year.
In the past year LTRN has reported a negative cash flow from operations.
LTRN had negative earnings in each of the past 5 years.
In the past 5 years LTRN always reported negative operating cash flow.
LTRN Yearly Net Income VS EBIT VS OCF VS FCFLTRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of LTRN (-110.50%) is worse than 77.67% of its industry peers.
Looking at the Return On Equity, with a value of -153.71%, LTRN is doing worse than 63.41% of the companies in the same industry.
Industry RankSector Rank
ROA -110.5%
ROE -153.71%
ROIC N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
LTRN Yearly ROA, ROE, ROICLTRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LTRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LTRN Yearly Profit, Operating, Gross MarginsLTRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, LTRN has more shares outstanding
LTRN has more shares outstanding than it did 5 years ago.
LTRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LTRN Yearly Shares OutstandingLTRN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LTRN Yearly Total Debt VS Total AssetsLTRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

LTRN has an Altman-Z score of -5.39. This is a bad value and indicates that LTRN is not financially healthy and even has some risk of bankruptcy.
LTRN has a Altman-Z score of -5.39. This is in the lower half of the industry: LTRN underperforms 61.54% of its industry peers.
LTRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.39
ROIC/WACCN/A
WACCN/A
LTRN Yearly LT Debt VS Equity VS FCFLTRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

LTRN has a Current Ratio of 3.52. This indicates that LTRN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LTRN (3.52) is comparable to the rest of the industry.
A Quick Ratio of 3.52 indicates that LTRN has no problem at all paying its short term obligations.
With a Quick ratio value of 3.52, LTRN perfoms like the industry average, outperforming 43.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.52
Quick Ratio 3.52
LTRN Yearly Current Assets VS Current LiabilitesLTRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

LTRN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.69%.
EPS 1Y (TTM)1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.71% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.28%
EPS Next 2Y-2.04%
EPS Next 3Y-3.21%
EPS Next 5Y-3.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LTRN Yearly Revenue VS EstimatesLTRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 20M 40M 60M
LTRN Yearly EPS VS EstimatesLTRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LTRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LTRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LTRN Price Earnings VS Forward Price EarningsLTRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LTRN Per share dataLTRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

LTRN's earnings are expected to decrease with -3.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.04%
EPS Next 3Y-3.21%

More info and screens

0

5. Dividend

5.1 Amount

LTRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LANTERN PHARMA INC

NASDAQ:LTRN (11/17/2025, 4:10:08 PM)

3.36

-0.02 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners20.97%
Inst Owner Change-3.83%
Ins Owners0.42%
Ins Owner ChangeN/A
Market Cap36.29M
Revenue(TTM)N/A
Net Income(TTM)-19.25M
Analysts82.86
Price Target20.4 (507.14%)
Short Float %2.8%
Short Ratio1.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.55%
Min EPS beat(2)15.97%
Max EPS beat(2)19.14%
EPS beat(4)3
Avg EPS beat(4)14.44%
Min EPS beat(4)-3.81%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)12.68%
EPS beat(12)10
Avg EPS beat(12)18.4%
EPS beat(16)12
Avg EPS beat(16)12.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.82%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.9
P/tB 2.9
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.65
OCFYN/A
SpS0
BVpS1.16
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.5%
ROE -153.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.36%
ROA(5y)-37.56%
ROE(3y)-54.18%
ROE(5y)-41.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.52
Quick Ratio 3.52
Altman-Z -5.39
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)166.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.14%
EPS Next Y3.28%
EPS Next 2Y-2.04%
EPS Next 3Y-3.21%
EPS Next 5Y-3.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.32%
EBIT Next 3Y-41.56%
EBIT Next 5Y-25.19%
FCF growth 1Y-26.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.08%
OCF growth 3YN/A
OCF growth 5YN/A

LANTERN PHARMA INC / LTRN FAQ

Can you provide the ChartMill fundamental rating for LANTERN PHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to LTRN.


Can you provide the valuation status for LANTERN PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to LANTERN PHARMA INC (LTRN). This can be considered as Overvalued.


How profitable is LANTERN PHARMA INC (LTRN) stock?

LANTERN PHARMA INC (LTRN) has a profitability rating of 0 / 10.


What is the expected EPS growth for LANTERN PHARMA INC (LTRN) stock?

The Earnings per Share (EPS) of LANTERN PHARMA INC (LTRN) is expected to grow by 3.28% in the next year.